Nierenberg Investment Management Company’s CytomX Therapeutics CTMX Stock Holding History

Nierenberg Investment Management Company’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$47.1K	Hold	12,555	–	–	0.02%	33
2026 Q1	$59K	Hold	12,555	–	–	0.03%	43
2025 Q4	$53.5K	Hold	12,555	–	–	0.03%	41
2025 Q3	$40K	Hold	12,555	–	–	0.02%	47
2025 Q2	$28.5K	Hold	12,555	–	–	0.02%	45
2025 Q1	$7.98K	Hold	12,555	–	–	﹤0.01%	57
2024 Q4	$12.9K	Hold	12,555	–	–	0.01%	51
2024 Q3	$14.8K	Hold	12,555	–	–	0.01%	53
2024 Q2	$15.3K	Buy	+12,555	New	+$25K	0.01%	53

Other funds holding CTMX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Swiss National Bank Zurich, Switzerland $191B AUM 45.21% 1-Year Est. Return

Nierenberg Investment Management Company's CTMX Position: Q2 2026 in Review

Nierenberg Investment Management Company held its CytomX Therapeutics (CTMX) position steady in Q2 2026 at 12,555 shares worth $47.1K. The position accounts for 0.02% of the portfolio, ranked #33.

Nierenberg Investment Management Company first reported a position in CTMX in Q2 2024 and has held it in 9 quarters since. The position peaked at $59K in Q1 2026. 80 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

Nierenberg Investment Management Company held 12,555 shares of CytomX Therapeutics worth $47.1K as of Q2 2026.
Nierenberg Investment Management Company left its CytomX Therapeutics share count unchanged in Q2 2026.
CytomX Therapeutics made up 0.02% of Nierenberg Investment Management Company's portfolio in Q2 2026, its #33 holding.
Nierenberg Investment Management Company first reported a position in CytomX Therapeutics in Q2 2024 and has held it in 9 quarters since.
Nierenberg Investment Management Company's CytomX Therapeutics position peaked at $59K in Q1 2026.
80 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Nierenberg Investment Management Company's 13F filing for Q2 2026, filed 11 Aug 2026.